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Abstract
Approximately one-third of patients on biologic therapy for rheumatoid arthritis (RA) receive them as monotherapy. There 
are few head-to-head randomised control trials comparing biologics as monotherapy. Our aim was to compare the efficacy 
and persistence of multimodal biologic agents as monotherapy in biologic naïve patients with RA in the real-world setting. A 
multicentre retrospective observational study was carried out comparing TNF inhibitors (TNFi), IL6 receptor inhibitor (IL6Ri) 
and CTLA-4 inhibitor (CTLA-4i) monotherapy in biologic naïve RA patients. The primary study outcome was DAS28 score 
at 6, 12, and 18 months. 126 patients were enrolled; 98 patients (78%) were taking TNFi, 19 patients (15%) IL6Ri and 10 (8%) 
CTLA-4i with similar baseline characteristics of sex and age across groups. Patients in the CTLA-4i group were more often 
seropositive and had greater numbers of comorbidities. At 6 and 12 months, patients in the IL6Ri group had a lower DAS28 
score compared to TNFi monotherapy. Those on CTLA-4i monotherapy also had a lower DAS28 score at 6 months than the 
TNFi group, although differences were lost by 12 months. Drug retention at 18 months was highest in the IL6Ri arm (68%) 
and CTLA-4i arm (80%) compared with only 55% in the TNFi group. Our findings support current guidance that IL6Ri should 
be considered in biologic naïve patients requiring biologic monotherapy, but also indicated that CTLA-4i could be an option.
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Introduction
Up to a third of rheumatoid arthritis (RA) patients on bio-
logic therapy do not take concurrent conventional synthetic 
disease-modifying antirheumatic drugs (csDMARDs) con-
trary to the recommendations from the most recent EULAR 
guidance. [1, 2] There are many reasons for this including 
adverse effects, poor drug adherence and contraindications 
to csDMARDs [3]. Despite this commonplace real-world 
practice, there are few head-to-head randomised control 
trials (RCTs) comparing biologic monotherapies to guide 
our prescribing and those published have limited follow-up 
periods of typically 24 weeks [3]. The ADACTA and MON-
ARCH trials showed superiority of IL6 receptor inhibitor 
(IL6Ri) monotherapy to adalimumab (a TNFi) monotherapy 
in reduction of DAS28 score at 24 weeks [4, 5]. Further-
more, large commercial RCTs frequently exclude patients 
with complex comorbidity, thus results are not always 
directly applicable in real-world settings. Aiming to address 
this knowledge gap, we compared the efficacy and persis-
tence of multimodal biologic agents as monotherapy in bio-
logic naïve patients with RA in the real-world setting focus-
ing specifically on the use of TNFi, IL6Ris and CTLA-4is.
Patients and methods
We conducted a retrospective observational study across 
four UK Rheumatology units. Ethical approval for the 
study protocol was sought and gained with the UK Health 
Research Authority following research ethics committee 
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review. Data were extracted from clinical biologic drug 
monitoring databases at each participating unit. Data were 
anonymised prior to analysis. All patients with a diagno-
sis of RA (as defined by their rheumatologist) initiating a 
biologic therapy without concurrent csDMARD therapy 
between 2012 and 2016 were included. In line with NHS 
prescribing policies, to be applicable for funding for bio-
logic monotherapy, all patients were either intolerant or 
had contraindications to csDMARDs. Only subcutane-
ous biologic agents were included. DAS28 scores had to 
be greater than 5.1 on two occasions to be applicable for 
funding through the National Health Service (NHS) for 
biologic therapy. To continue to receive NHS funding for 
biologic therapy, patients must show initial and contin-
ued response to treatment as demonstrated by a reduction 
in DAS28 score. Patients are assessed routinely at base-
line and then at every 6 months thereafter to comply with 
national guidance. Due to the recognised effect of IL6-i 
on CRP, we only included DAS28 score calculated using 
the ESR.
Patients on concurrent csDMARDs, long-term steroids 
or previous bDMARD exposure were excluded. During 
the study, some patients may have received short courses 
of oral steroids or intraarticular steroids if they had a flare 
of disease. Due to the ad hoc nature of these prescriptions, 
it was not possible to collect these data. However, at a 
patient’s 6-month review, routine questioning identifying 
repeated disease flares would be an indication of failure of 
biologic treatment prompting change in treatment which 
would be recorded.
Baseline demographical data was collected including 
age, sex, seropositivity status using rheumatoid factor 
(RF) or presence of anti-citrullinated protein antibodies 
(ACPA) where available and presence of comorbidities 
(specifically including malignancy, diverticulitis, severe 
infection, heart failure, ischaemic heart disease, demyeli-
nating disease, tuberculosis, diabetes or interstitial lung 
disease). Rationale for prescription of biologic agent as 
monotherapy was also recorded.
We compared biologic classes TNFi, IL6Ri and 
CTLA-4 inhibitors. The primary outcome was absolute 
DAS28 at 6, 12 and 18 months.
Covariates were pre-defined according to their potential 
association with the outcome, including age, sex, seroposi-
tivity status using ACPA or RF, comorbidities (including 
malignancy, demyelinating disease diverticulitis, severe 
infection, heart failure, ischaemic heart disease, tuberculo-
sis, diabetes or interstitial lung disease), previous DMARD 
history and the reason for discontinuation; baseline 
DAS28-ESR was recorded with individual components. 
Drug exposure duration was recorded.
Statistical analyses
Comparison of patient and disease characteristics between 
the treatment groups was performed using ANOVA and 
Kruskal–Wallis test for normal and non-normally distributed 
variables and Chi-squared or Fisher’s exact test for categori-
cal variables.
At each time point, we used weighted logistic regression 
with drug group as the only independent variable (TNFi 
as the reference) and each outcome measure in turn as the 
dependent variable. Covariates were balanced using match-
ing weights. Multigroup propensity score (PS) matching 
excludes many individuals and is computationally demand-
ing. In our case, where each group size is relatively small, 
matching would be prohibitive for analysis. Matching 
weights are an extension of inverse probability of treatment 
weighting (IPTW), which emulates a PS-matched popula-
tion. This method retains all individuals in the analysis and 
thus the advantage of superior mean squared error, particu-
larly in the case of unequal sized groups and poor covariate 
overlap [6]. Briefly, it replaces the IPTW numerator with the 
smallest PS of each treatment group. A multinomial logistic 
model was used to construct IPTW for each treatment group. 
Independent variables for the IPTW model included all base-
line covariates as well as all baseline outcome measures.
Missing outcomes at each time point are unlikely to be 
random thus leading to bias. We therefore used inverse prob-
ability of censoring weights (IPCW) to make missingness 
random with respect to baseline variables, as follows: the 
numerator is the predicted probability from logistic mod-
els of not being missing conditioned on treatment group, 
the denominator additionally conditioned on covariates. To 
generate the above weights, multinomial and logistic models 
required complete data for all covariates. Multiple imputa-
tion was performed using chained equations (-mi impute 
mice- command in Stata v14). All variables in each IPW 
model were included in the respective imputation models, 
with 30 imputed datasets.
Results
Patient characteristics
We recruited 126 patients. Reasons for prescriptions of bio-
logic agents as monotherapy included previous adverse reac-
tions to csDMARDs resulting in gastrointestinal side effects, 
rashes, blood dyscrasias or hepatotoxicity, while for other 
patients csDMARDs were contraindicated.
Baseline characteristics are shown in Table 1. 98 patients 
(78%) were taking TNFi, this group comprised etanercept 
(76 patients), adalimumab (10 patients), certolizumab (5 
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patients) and golimumab (7 patients). 19 patients (15%) 
were on an IL6Ri and 10 (8%) CTLA-4i. Of those on TNFi, 
the proportion of females on each biologic and patient age 
was similar across all drugs. Patients starting IL6Ri had 
significantly shorter disease duration. A greater proportion 
of patients on CTLA-4i and TNFi had more comorbidities 
than TNFi (Table 2) and those in the CTLA-4i were more 
likely to have multiple comorbidities at baseline. Those on 
CTLA-4i were more likely to be seropositive. Baseline dis-
ease activity according to DAS28 and its components were 
generally comparable.
Comparison of DAS28 scores across drug groups
Compared to patients on TNFi at 6 months, DAS28 was 
lower for patients on IL6Ri by 1.84 units (95% CI − 2.57, 
− 1.11) and CTLA-4i by 0.33 units (95% CI − 0.60, − 1.25). 
At 12 months, DAS28 was lower in patients on IL6Ri [0.90 
units (95% CI − 1.90, 0.13)] and CTLA-4i [0.24 units (95% 
CI − 1.46, 0.97)] compared to TNFi. At 18 months, those 
on IL6Ri scored 0.90 units lower (95% CI − 1.90, 0.13) and 
CTLA-4i 0.80 units higher (95% CI 0.09, 1.53) than TNFi. 
IL6Ri led to a striking reduction in ESR compared to TNFi 
at all time points. At both 12 months and 18 months, IL6i 
and CTLA-4i led to significantly fewer swollen joints than 
those on TNFi (Table 3).
More patients in the IL6Ri and CTLA-4i groups reached 
EULAR DAS28 defined remission at 18 months (54% and 
50%, respectively) compared with only 39% in the TNFi 
group. The percentage of patients reaching low disease 
activity (DAS28 < 3.2) at 18 months in the IL6Ri group 
was higher (85%) compared with 63% in both other drug 
groups. These results may explain why drug retention was 
greater in the non-TNFi groups at 18 months: 68% in the 
IL6Ri group and 80% in CTLA-4i versus 55% in the TNFi 
group. At the end of follow-up, inefficacy was the reason 
for discontinuation of biologic therapy in 18% of patients 
on TNFi compared with only 5% on IL6Ri and 10% on a 
CTLA-4i. Adverse reactions caused cessation of biologic 
treatment in 13% of patients initiated on TNFi, whereas in 
the IL6Ri it was 21% and the CTLA-4i, 30%.
Table 1  Baseline characteristics
* Data incomplete for autoantibodies
TNFi TNF inhibitor, IL6Ri IL6 receptor inhibitor, CTLA-4i CTLA-4 inhibitor, RF rheumatoid factor, ACPA 
anti-citrullinated protein antibodies, VAS visual analogue scale (0–100 mm)
n All TNFi IL6Ri CTLA-4i p value
98 19 10
Mean age, years (SD) 60.9 ( 12.0) 62.4 (12.4) 62.3 ( 11.4) 0.84
Female, n (%) 77 (79%) 12 (63%) 7 (70%) 0.33
Disease duration, n (%)
 1–2 years 1 (1%) 4 (21%) 1 (10%) 0.001
 3–4 years 18 (18%) 6 (32%) 1 (10%)
 ≥ 5 years 79 (81%) 9 (47%) 8 (80%)
RF positive*, n (%) 36 (59%) 4 (50%) 4 (80%) 0.590
ACPA positive*, n (%) 50 (72%) 6 (67%) 5 (100%) 0.417
RF or ACPA seropositive*, n (%) 68 (69%) 9 (47%) 9 (90%) 0.065
Mean number of comorbidities (SD) 0.3 (0.7) 0.8 (1.2) 1.4 (1.6)  < 0.001
DAS28-ESR, mean (SD) 6.1 (0.9) 6.3 ( 0.9) 6.3 (0.8) 0.50
Tender joint count, median (IQR) 12.0 (8.0, 18.0) 13.0 (9.0, 21.0) 14.0 (11.0, 15.0) 0.45
Swollen joint count, median (IQR) 6.0 (3.0, 9.0) 5.0 (4.0, 8.0) 5.5 (3.0, 7.0) 0.61
Median ESR, mm/hr (IQR) 33.0 (19.0, 52.0) 34.0 (17.0, 76.0) 34.0 (12.0, 98.0) 0.71
Global VAS, mean (SD) 78.2 (19.3) 79.6 (19.4) 82.6 (15.1) 0.77
Table 2  Comorbidities at baseline
TNFi IL6Ri CTLA-4i
Number with available data 55 14 8
Malignancy 0 1 1
Demyelinating disease 0 0 0
Diverticulitis 3 1 0
Cardiac failure 0 0 0
Atherosclerotic disease 5 2 0
TB 2 0 0
Diabetes 1 1 2
Interstital lung disease 0 2 1




In this study using real-world data, IL6Ri led to lower 
DAS28 at 6 and 12 months compared to TNFi monother-
apy, although differences were attenuated by 18 months. 
Similarly, CTLA-4i monotherapy resulted in lower DAS28 
at 6 months than TNFi, although superiority was lost by 
12 months. Drug persistence at 18 months was great in the 
CTLA-4i and IL6Ri groups than those on TNFi.
To date, there is only one head-to-head RCT of CTLA-4i 
with the TNFi adalimumab, however, all patients were on con-
current methotrexate [7]. Our study demonstrated significant 
reduction of SJC at 18 months and comparably low DAS28 
score for those on CTLA-4i versus TNFi. Notably, those on 
CTLA-4i had more comorbidities (a typically more challeng-
ing group to treat), the high drug retention of 80% at 18 months 
would support the use of CTLA-4i in this cohort. These real-
world data are particularly useful as the BSR biologics regis-
try does not include CTLA-4i monotherapy so there is little 
published data on this cohort. The observational study by Jor-
gensen et al. compared biologic monotherapy (including those 
on TNFi, CTLA-4i and IL6Ri) and disease activity at 6 months 
only [8]. The study did not adjust for potential confounding 
factors. It included patients both newly started on the drug 
during the study period and those started on it prior to study 
initiation, although post hoc statistical analysis found there 
was no difference in drug adherence between groups or CDAI 
remission rates. Furthermore, 22% of all patients included 
were on long-term prednisolone complicating the analysis. 
Like the study by Bachkaus et al. (which compared TNFi and 
Tocilizumab mono therapy), Jorgensen et al. included patients 
who had been on multiple biologic therapies previously which 
could indicate harder-to-treat disease [9]. In a further study by 
Jorgenson et al., no adjustment for potential confounders has 
been included therefore the results are open to confounding 
by indication [10].
By contrast, our study design including only biologic 
naive patients and adjustment for potential confounding fac-
tors including comorbidities, seropositivity and age amongst 
others makes the results more easily interpretable. Due to the 
study design relying on retrospective data collection, there 
were some data points missing particularly in regard to sero-
positivity status of patients, however, our statistical analysis 
took account of this.
Key strengths of this study included examination of DAS28 
components. We showed that IL6Ri had profound impact on 
ESR, as expected, but also a lower SJC for IL6i and CTLA-4i 
monotherapies. Our duration of follow-up was also longer than 
typical RCTs, allowing us to see CTLA-4i may be more effica-
cious initially, but not at long-term follow-up. Our study was 
limited by the lack of other outcomes including CRP. Patients 
enrolled in this study had high disease activity with baseline 
median DAS28 scores 6.1–6.3 across the drug groups. We 
recognise that in some clinical contexts, patients maybe com-
menced on biologic monotherapy with less active disease. Fur-
thermore, caution should be taken drawing conclusions from 
our small sample size in particular relating to the IL6i and 
CTLA-4i groups. However, the effect size of TNFi vs IL6Ri 
comparison was similar to randomised trials [4].
Conclusion
Our findings support EULAR guidance that IL6Ri should 
be considered as a first-line biologic in the biologic naive 
patient requiring monotherapy [2]. However, CTLA-4i may 
also have a role in this patient population and further stud-
ies of larger patient numbers are needed to investigate this 
further.
Table 3  DAS28 and components thereof compared against TNF inhibitors at each time point
IL6Ri IL6 receptor inhibitor, CTLA-4i CTLA-4 inhibitor, SJC swollen joint count, TJC tender joint count, ESR (mm/hr), VAS Patient Global 
Visual Analogue scale
6 months 12 months 18 months
Coefficient (95% CI) P value Coefficient (95% CI) P value Coefficient (95% CI) P value
IL6Ri DAS28 − 1.84 (− 2.57, − 1.11) < 0.001 − 1.69 (− 2.30, − 1.07)  < 0.001 − 0.88 (− 1.90, 0.31) 0.087
SJC − 0.88 (− 1.95, 0.19) 0.110 − 1.25 (− 1.93, − 0.57) 0.001 − 1.85 (− 3.48, − 0.22) 0.030
TJC − 2.11 (− 4.46, 0.22) 0.080 − 1.48 (− 2.90, − 0.07) 0.040 0.25 (− 0.39, 0.88) 0.440
ESR − 22.00 (− 27.35, − 17.60)  < 0.001 − 15.00 (− 22.01, − 7.92)  < 0.001 − 15.93 (− 32.04, 0.18) 0.053
VAS − 8.50 (26.70, 8.70) 0.330 − 13.70 (− 35.36, 7.96) 0.210 − 6.89 (− 20.72, 6.94) 0.330
CTLA-4i DAS28 − 0.33 (− 0.60, 1.25) 0.480 − 0.24 (− 1.50, 0.97) 0.690 0.81 (0.09, 1.53) 0.030
SJC − 0.79 (− 1.97, − 0.40) 0.190 − 0.76 (− 1.83, 0.32 0.170 − 1.57 (− 3.00, − 0.18) 0.030
TJC 5.98 (− 3.21, 15.16) 0.200 1.65 (− 2.56, 5.86) 0.440 2.59 (− 0.26, 5.37) 0.080
ESR − 13.09 (− 25.55, − 0.63) 0.040 11.63 (− 25.67, 48.94) 0.540 − 3.02 (− 39.82, 33.78) 0.870
VAS − 4.22 (− 15.28, 6.82) 0.450 − 12.85 (− 34.52, 8.83) 0.240 25.49 (− 4.03, 55.00) 0.090
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